Form 4: Cytokinetics CEO Robert Blum Sells Shares to Cover Vesting of Restricted Stock Units
SEC Form 4 Filing
Cytokinetics' CEO, Robert Blum, sold 8,743 shares of common stock at $42.88 to cover a transaction related to the vesting of restricted stock units.
Summary
- On March 3, 2025, Robert I. Blum, the President and CEO of Cytokinetics Inc., sold 8,743 shares of Cytokinetics' common stock.
- The sale was executed at a price of $42.88 per share.
- The transaction was conducted to cover obligations related to the vesting of restricted stock units.
- Following the transaction, Mr. Blum directly owns 406,151 shares of Cytokinetics' common stock.
- Mr. Blum also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to stock transactions. It doesn't convey strong positive or negative sentiment.
Industry Context
Executive stock sales are a common occurrence, often related to compensation and tax planning. The sale itself doesn't necessarily indicate a negative outlook on the company, especially when it's related to covering vesting obligations.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders due to the small volume of shares sold relative to the total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of the stock sale transaction. |
| 03/05/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.